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Abstract: Despite longstanding recognition of thymic epithelial neo-
plasms, there is no official American Joint Committee on Cancer/
Union for International Cancer Control stage classification. This 
article summarizes proposals for classification of the T component 
of stage classification for use in the 8th edition of the tumor, node, 
metastasis classification for malignant tumors. This represents the 
output of the International Association for the Study of Lung Cancer 
and the International Thymic Malignancies Interest Group Staging 
and Prognostics Factor Committee, which assembled and analyzed 
a worldwide database of 10,808 patients with thymic malignancies 
from 105 sites. The committee proposes division of the T compo-
nent into four categories, representing levels of invasion. T1 includes 
tumors localized to the thymus and anterior mediastinal fat, regard-
less of capsular invasion, up to and including infiltration through the 
mediastinal pleura. Invasion of the pericardium is designated as T2. 
T3 includes tumors with direct involvement of a group of mediasti-
nal structures either singly or in combination: lung, brachiocephalic 
vein, superior vena cava, chest wall, and phrenic nerve. Invasion of 
more central structures constitutes T4: aorta and arch vessels, intra-
pericardial pulmonary artery, myocardium, trachea, and esophagus. 
Size did not emerge as a useful descriptor for stage classification. 
This classification of T categories, combined with a classification 
of N and M categories, provides a basis for a robust tumor, node, 
metastasis classification system for the 8th edition of American Joint 
Committee on Cancer/Union for International Cancer Control stage 
classification.
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(J Thorac Oncol. 2014;9: S73–S80)
Thymic epithelial neoplasms are a rare but well-established group of organ-specific neoplasms with varying malignant 
potential that comprise thymomas, thymic carcinomas (TC) 
and thymic neuroendocrine tumors (NETT). However, despite 
their longstanding recognition, there has never been an official 
American Joint Committee on Cancer/Union for International 
Cancer Control (AJCC/UICC) stage classification, perhaps 
in part due to their relative rarity. At least 15 different stage 
classification systems have been proposed, beginning as far 
back as 1978. The various classification systems and their dif-
ferences have been recently reviewed1 with the most widely 
known system being the Masaoka system.2 This was proposed 
in 1981 on the basis of an experience with 91 patients, with 
most other systems being based on roughly similar, relatively 
small cohorts of patients. The Masaoka system was refined to 
the Masaoka-Koga system3 and remains the most widely used 
system currently.
The International Thymic Malignancies Interest Group 
(ITMIG) and the International Association for the Study of 
Lung Cancer (IASLC) more or less simultaneously set out to 
accomplish a staging system for thymic epithelial neoplasms, 
and subsequently joined forces in 2010, partnering to cre-
ate a Thymic Domain of the Staging and Prognostic Factors 
Committee (TD-SPFC), charged with the development of 
Copyright © 2014 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/14/0909-0S73
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: 
Proposals for the T component for the Forthcoming (8th) 
Edition of the TNM Classification of Malignant Tumors
Andrew G. Nicholson, MD,* Frank C. Detterbeck, MD,† Mirella Marino, MD,‡ Jhingook Kim, MD,§ 
Kelly Stratton, MS,║ Dorothy Giroux, MS,║ Hisao Asamura, MD,¶ John Crowley, PhD,║ Conrad Falkson, 
MBChB,# Pier Luigi Filosso, MD,** Giuseppe Giaccone, MD,†† James Huang, MD,‡‡ Kazuya Kondo, 
MD,§§ Marco Lucchi, MD,║║ Edith M Marom, MD,¶¶ Meinoshin Okumura, MD,## Enrico Ruffini, 
MD,** and Paul Van Schil, MD,*** on behalf of the Staging and Prognostic Factors Committee†††, 
Members of the Advisory Boards,‡‡‡ and Participating Institutions of the Thymic Domain§§§
*Pathology, Royal Brompton Hospital, London, United Kingdom; †Thoracic 
Surgery, Yale University, New Haven, Connecticut; ‡Pathology, Regina 
Elena National Cancer Institute, Rome, Italy; §Thoracic Surgery, Samsung 
Medical Center, Seoul, South Korea; ║Biostatistics, Cancer Research And 
Biostatistics, Seattle, Washington; ¶Thoracic Surgery, National Cancer 
Center Hospital, Tokyo, Japan; # Radiation Oncology, Queen’s University, 
Ontario, Canada; **Thoracic Surgery, University of Torino, Torino, Italy; 
††Medical Oncology, Georgetown University, Washington, District of 
Columbia; ‡‡Thoracic Surgery, Sloan Kettering Cancer Center, New York, 
New York; §§Thoracic Surgery, University of Tokushima, Tokushima, 
Japan; ║║Thoracic Surgery, University of Pisa, Pisa, Italy; ¶¶Radiology, 
MD Anderson Cancer Center, Houston, Texas; ##Thoracic Surgery, Osaka 
University, Osaka, Japan; and ***Thoracic Surgery, Antwerp University 
Hospital, Antwerp, Belgium. 
†††See Appendix 1; ‡‡‡see Appendices 2, 3, and 4; and §§§see Appendix 5.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Frank C. Detterbeck, MD, Department of 
Surgery, Division of Thoracic Surgery, Yale University School of 
Medicine, BB205 333 Cedar Street, New Haven, Connecticut. E-mail: 
frank.detterbeck@yale.edu
ITMIG DEFINITIONS AND POLICIES
S74 Copyright © 2014 by the International Association for the Study of Lung Cancer
Nicholson et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 9, Supplement 2, September 2014
proposals to AJCC/UICC for the eight edition of the stage 
classification system. ITMIG provided the engagement of the 
vast majority of clinicians and researchers active in these dis-
eases, and IASLC provided funding for the project and sta-
tistical analysis and its expertise in developing proposals for 
stage classification. Retrospective and prospective databases 
were created to allow global collection of cases.4
Initial discussion formed the view that (1) a system 
based on tumor, node, metastasis (TNM) staging was prefer-
able and (2) the staging system should be applicable to all 
three major subgroups of thymic epithelial neoplasms, not 
least as there is overlap between tumor subtypes.5 This would 
therefore be consistent with staging systems for other organs.
Members of the committee were divided into groups to 
look at T, N, and M components individually, in similar fash-
ion to the IASLC staging project for the 7th edition of lung 
cancer staging.6–9 This article describes the development of 
proposals for the descriptors of the T component for the 8th 
edition of TNM classification system.
METHODS
ITMIG and IASLC partnered with other organizations 
devoted to thymic disease to create a collaborative world-
wide database involving 105 institutions and 10,808 patients 
(Supplementary Figure 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A663), as has been described pre-
viously.4 Of these, 2663 of the patients (25%) were excluded 
(due to missing endpoints in 1921 [18%], date errors in 62, 
first treatment before 1990 in 258 [2%], and missing stage or 
diagnosis data in 422 [4%]), leaving 8145 of patients for analy-
sis. Most of the cases were first treated between 2000 and 2010 
(Supplementary Figure 2, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A664). The vast majority of patients 
were treated with surgery, reflecting both the predominance 
of this treatment modality and that surgeons and pathologists 
were more able to provide data (Fig. 1). Data were available on 
the pathologic stage in 8084 patients, on the clinical stage in 
5232 patients, on survival in 8145 patients (this was one of the 
inclusion criteria), and on recurrence in 4732 patients. Specific 
data on involved structures were reported in 7197, with one 
dimension of size in 6441 and with more than one dimension 
in 286 patients. Resection status was noted in 7726 patients (R0 
in 6621, R1 or R2 in 1105). Further details of patients available 
for analysis by invaded structures are shown in Supplementary 
Table 1 (Supplemental Digital Content 3, http://links.lww.com/
JTO/A665).
For the assessment of the T component, the TD-SPFC 
assessed the impact of involvement of various mediastinal 
structures. Data were collected for extent of direct invasion 
beyond tumor capsule into mediastinal structures (wholly 
encapsulated, limited to mediastinum, mediastinal pleura, 
pericardium, lung, superior vena cava, brachiocephalic artery 
and vein, phrenic nerve, chest wall, pulmonary artery, aorta 
and myocardium), using recently updated histological defi-
nitions based on parameters in the Masaoka-Koga staging 
system.10
The TD-SPFC focused on the endpoints of recurrence 
and survival. In thymic malignancies, these are not closely 
linked (recurrence does not necessarily lead to death and 
deaths are often not due to recurrence). Recurrence is prob-
ably the best measure in less advanced tumors.11 Focusing on 
only R0 resected patients has the effect of equalizing one of 
the major treatment modalities. However, this is most appli-
cable to less advanced tumors; the more extensive tumors that 
are resected likely represent an increasingly selected cohort 
(see Supplemental Figure 3, Supplemental Digital Content 
4, http://links.lww.com/JTO/A666). Survival in all patients 
regardless of resection status may be the best outcome mea-
sure in more advanced tumors, but outcomes then reflect a 
combination of the effect of the tumor extent itself and effi-
cacy of treatment. As a result of these considerations, the 
TD-SPFC considered recurrence in R0 resected patients, and 
overall survival in both R0 and all patients regardless of resec-
tion status. No further stratification by treatment was possible.
Actuarial and cumulative incidence curves relative to 
these endpoints were generated from multiple different view-
points, exploring details of relationships, and factors such as 
histological type and subtype (thymoma versus thymic car-
cinoma and World Health Organization A + AB + B1 versus 
B2 + B3), type of staging system (Masaoka versus Masaoka-
Koga), geographic region (Asia versus Europe versus North 
and South America; also Japan versus rest), and other param-
eters. During this process, approximately 500 different graphs 
were reviewed by the TD-SPFC. The initial assessment 
involved visual scrutiny of the curves and consideration of 
clinical relevance. This allowed the TD-SPFC to achieve an 
understanding of the data, the limitations, and the pitfalls, and 
to develop a structure for more detailed statistical analysis.
Statistical analysis of the data was carried out by the 
Cancer Research and Biostatistics (CRAB) organization using 
the SAS System for Windows version 9.3. Overall survival 
(OS) was estimated by the method of Kaplan and Meier,12 and 
curves were compared using the logrank test.13 The cumulative 
FIGURE 1.  Overview of the data set by treatment modality. 
Overview of data available for analysis by treatment modality 
used. Among cases with known treatment modalities used, 
surgery was included in 99%. Chemo, chemotherapy; RT, 
radiotherapy.
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incidence of recurrence (CIR), which accounts for the pres-
ence of the competing risk of death,14 was used to estimate 
recurrence. For both OS and CIR, outcome was measured 
from the date of first intervention (as this was the baseline 
date captured in the database) and patients were censored at 
the date of last follow-up.
To assess the impact of size on OS, patients with one-
dimensional tumor size (n = 5796) were allocated at random 
to either a learning set (for the identification of a cut point for 
size) that comprised two-thirds of the sample or a validation 
set (for testing that cut point, if a significant cut point was 
identified) that comprised the remaining one-third. The allo-
cation was stratified by pathologic Masaoka or Masaoka-Koga 
stage, continent on which the patient was treated, and tumor 
size greater than 10 cm or not to ensure that these factors were 
distributed similarly within the two sets. Patients treated with 
neoadjuvant chemotherapy or radiotherapy were excluded 
from these analyses. Two methods for choosing tumor size 
cut points were then applied to the learning set, and outcomes 
from the resultant cut points were then compared in the valida-
tion set. In the first approach, running logrank statistics were 
used to identify a cut point for tumor size that best separated 
patients based on outcome.15 In the second, a recursive parti-
tioning and amalgamation algorithm was used to identify a cut 
point for size and groupings,16 based on Masaoka or Masaoka-
Koga stage and histological type.
PROPOSED T CaTEGORIES
Overall approach by “Levels” of Invasion 
Initial analyses of potential descriptors of the T component 
were complex, and many different approaches were assessed. 
The complexity was due to (1) the number of structures that 
could be involved, (2) involvement could include only one struc-
ture or several structures, and (3) involvement of some structures 
implied involvement of another, but this may be underreported 
(e.g., involvement of the lung implies involvement of the medi-
astinal pleura although this was not always reported).
After informal inspection of outcome data for various 
cohorts defined according to patterns of invasion, the commit-
tee settled on an approach based on “levels” of involvement 
(Table 1). This meant that a tumor would be counted in a certain 
“level” of involvement if either one or more than one structure 
of that level is involved, with or without explicit involvement of 
structures included in a lower level. This approach was chosen 
because it allowed management of complexities as described 
above, and it was supported by survival and recurrence out-
comes that demonstrated no difference for a particular level 
whether or not a lower level structure was reported as involved. 
Structures were grouped into a level primarily based on how 
similar or distinct the survival and recurrence outcomes were, 
but also took into account anatomical considerations and inter-
preted the results in light of limitations of the database (e.g., 
limited data on unresected patients).
T1—Localized to Thymus and Perithymic Fat
T1 includes tumors that are encapsulated and tumors 
that extend beyond a capsule into the anterior (perithymic) fat. 
Thus, T1 includes tumors that were classified as stage I or II 
in the Masoaka or Masaoka-Koga stage classification systems. 
It also includes tumors classified as either stage IIa or IIb in 
either of these systems.
Inclusion of these various tumors in T1 was based on 
the fact that there was no consistent difference in outcomes 
(recurrence or survival) among the Masaoka or Masaoka-
Koga groups or subgroups (Fig. 2 and Supplementary 
Figure 4, Supplemental Digital Content 5, http://links.lww.
com/JTO/A667). In only a few analyses was there a sugges-
tion of a small difference (CIR by c-stage and in Japanese 
Association for Research in the Thymus cases); however 
because these small differences were not borne out in other 
analyses, they did not, in the opinion of the TD-SFPC, justify 
further separation.
In addition, there was no clinically significant differ-
ence across multiple analyses in outcomes of patients with 
tumors that were otherwise confined to the thymus or peri-
thymic fat (i.e., T1) whether the mediastinal pleura was 
recorded as being involved or not. There is also a general per-
ception among many pathologists that it is difficult to iden-
tify the mediastinal pleura microscopically.17 Furthermore, 
the crude rate of recurrence or death with only mediastinal 
pleura involvement was similar to other T1 tumors (Table 2). 
However, there is a slight difference in CIR in patients from 
Japan submitted by the Japanese Association for Research in 
the Thymus. Therefore, the TD-SPFC decided, to gain more 
prospective data for further testing, to subcategorize T1 into 
T1a (no mediastinal pleural involvement) and T1b (involve-
ment of the mediastinal pleura). This involvement should be 
pathologically confirmed.
TaBLE 1.  T Categories and Descriptors
T Descriptors
T1 A tumor that either is limited to the thymus with or without 
encapsulation, directly invades into the mediastinum only 
or directly invades the mediastinal pleura but does not 
involve any other mediastinal structure
For further testing, T1 is subdivided into T1a (no mediastinal 
pleural involvement) and T1b (direct invasion of the 
mediastinal pleura)
(Level 1 structures—thymus, anterior mediastinal fat, 
mediastinal pleura)
T2 A tumor with direct invasion of the pericardium (either 
partial or full-thickness)
(Level 2 structures—pericardium)
T3 A tumor with direct invasion into any of the following: lung, 
brachiocephalic vein, SVC, phrenic nerve, chest wall, or 
extrapericardial pulmonary artery or veins
(Level 3 structures—lung, brachiocephalic vein, SVC, 
phrenic nerve, chest wall, hilar pulmonary vessels)
T4 A tumor with invasion into any of the following: aorta 
(ascending, arch, or descending), arch vessels, 
intrapericardial pulmonary artery, myocardium, trachea, 
esophagus
(Level 4 structures—aorta [ascending, arch, or descending], 
arch vessels, intrapericardial pulmonary artery, 
myocardium, trachea, esophagus)
T categories are defined by “levels” of invasion; they reflect the highest degree of 
invasion regardless of how many other (lower level) structures are invaded.
SVC, superior vena cava.
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T2—Involvement of Pericardium
T2 denotes tumor with direct invasion of the pericar-
dium (either partial or full-thickness). For pathologic staging, 
this must be microscopically confirmed; invasion is defined as 
invasion into the fibrous (parietal) pericardium. The pericar-
dium is the only structure included in the T2 level.
The pericardium is the most often involved mediasti-
nal structure (after the mediastinal pleura). Identification of 
pericardial involvement microscopically is straightforward 
(in contrast to the mediastinal pleura). Although radiographic 
identification of pericardial involvement (i.e., clinical staging) 
may be imprecise, it is easy to identify a suspicion of involve-
ment when the tumor abuts the pericardium. From a surgical 
perspective, resection of a potentially involved portion of peri-
cardium is straightforward.
Involvement of the pericardium resulted in a worse 
rate of recurrence and survival in patients than those with 
T1 involvement (either with or without mediastinal pleural 
involvement) (Fig. 2). Furthermore, recurrence was lower 
than for involvement of level 3 structures.
T3—Involvement of Lung, Brachiocephalic 
Vein, Vena Cava, Phrenic Nerve, Chest Wall
Involvement of the lung, brachiocephalic vein, superior 
vena cava, phrenic nerve, or chest wall is classified as T3. This 
includes involvement of one or several of these structures, and 
is classified the same whether lower level tissues (e.g., peri-
cardium) are involved or not. Hilar vascular structures such as 
extrapericardial pulmonary artery or pulmonary veins are also 
classified as T3.
An extensive analysis underlies this definition. There 
are many different ways one could address involved struc-
tures, given the number of different structures involved and 
possible combinations. Involvement of each single structure 
alone was compared (including pericardium and mediasti-
nal pleura); there were no apparent differences, except that 
mediastinal pleural involvement was only associated with few 
recurrences (Supplementary Figure 5, Supplemental Digital 
Content 6, http://links.lww.com/JTO/A668). Various ways of 
combining involved structures, and whether involvement of 
a single structure should be classified differently from when 
multiple structures are involved were considered. The lack of 
a consistent difference and the advantage of simplicity led 
to the proposed grouping by level of invasion, consisting of 
one or more structures involved within a level (±lower level 
involvement). Furthermore, from a treatment (i.e., surgical) 
standpoint, the complexity of involvement of level 3 struc-
tures is similar and distinctly better than involvement of level 
4 structures, and worse than involvement of pericardium only.
The proposed definition of T3 results in a progressive 
increase in the rate of recurrence (Fig. 2 and Tables 2 and 3). 
Recurrence was deemed the more informative outcome for 
this issue. OS was similar for T2 and T3. Some nuances of 
observed outcomes deserve mention. Involvement of a single 
level 3 structure resulted in lower recurrence rates than multi-
ple level 3 structures (10-year CIR 36% [95% CI, 32–41] ver-
sus 57% [95% CI, 41–72]). However, the CIR for single level 3 
involvement was higher than that for pericardial (T2) involve-
ment (10-year CIR 25% [95% CI, 21–29]). Nevertheless, after 
considering multiple different outcomes, ways of grouping 
FIGURE 2.  Outcomes of all patients by T categories. Outcomes for all patients with a thymic malignancy of any type (e.g., 
thymoma, thymic carcinoma, neuroendocrine tumor, and other). A, Cumulative incidence of recurrence, R0 resected patients; 
(B) overall survival, R0 resected patients; and (C) overall survival, all patients (any R status). Point estimates at 5 and 10 years are 
provided in the tables. See Table 3 for statistical significance of the differences between the T categories. CI, 95% confidence 
interval; Cum. Inc., cumulative incidence; N, total number of evaluable patients; OS, overall survival; R0, complete resection; Yr, 
year.
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structures, and practical (simplicity) and surgical aspects, the 
proposed T3 category was felt to be consistent with outcome 
data, clinically relevant and practically applicable.
T4—Involvement of aorta, Pulmonary artery, 
Myocardium, arch Vessels, Trachea, Esophagus 
T4 structures include the myocardium, the intrapericar-
dial pulmonary artery, the aorta (ascending, arch, or descend-
ing), the arch vessels (brachiocephalic, carotid, and subclavian 
arteries), the trachea, and the esophagus. These are grouped as 
level 4 structures and distinguished from level 3 (T3) structures.
To assess the impact of T4, OS in all patients regard-
less of R status was considered to be most informative. There 
was a trend to worse OS for T4 versus T3; but there were 
insufficient cases to support statistical inference (Fig. 2 and 
Tables 2 and 3). The number of patients available for analy-
sis with T4 involvement was limited, reflecting the fact that 
the retrospective database was largely produced by surgeons 
and pathologists. Even the patients who were operated on but 
not completely resected likely represent only a subset of all 
T4 patients. Specifically, data were available on 31 patients 
with aortic, 21 with arch vessel, 20 with pulmonary artery, 
and one with myocardial involvement; insufficient numbers 
of patients were available for analysis with esophageal or tra-
cheal involvement.
Involvement of T4 structures presents major complexity 
from the standpoint of surgical resection. Such involvement 
can be suspected from imaging. Furthermore, this classifica-
tion of structures as T4 is consistent with the classification 
for lung cancer. Therefore, the proposed T4 category is clini-
cally applicable, practical, and appears to be supported by out-
come data (recognizing that outcomes for all T4 patients are 
almost certainly worse than that of the selected patients in the 
database).
Tumor Size
Among the patients with the necessary covariates for 
the size analyses, a single dimension of tumor size was avail-
able in 5796 cases; there were insufficient cases (n = 231) 
with greater than one dimension measurements to allow a 
meaningful analysis of area or volume. Using a training and 
validation set (n = 3828 and 1968 for any R and 3365 and 
1715 for R0, respectively), a running log rank statistical analy-
sis was performed to identify relevant cut points for tumor 
size. Ten cm was identified as the only valid cut point among 
the any R cohort (Supplementary Figure 6A, Supplemental 
Digital Content 7, http://links.lww.com/JTO/A669); in the R0 
cohort, 9.5 cm was the best cut point but it was not statistically 
significant. Overall, survival curves demonstrated a difference 
in the any R cohort. However, this difference was entirely 
due to a difference in outcomes among incompletely resected 
patients; there was no difference whatsoever among R0 
patients (Supplementary Figure 6C, D, Supplemental Digital 
Content 7, http://links.lww.com/JTO/A669). Further analy-
sis stratifying by Masaoka/Masaoka-Koga stage showed that 
size was only predictive among stages III, IV R1,2 patients. 
A recursive partitioning analysis was performed to assess 
the importance of size relative to other tumor features. This 
also showed that other staging characteristics were dominant 
in separating groups by prognosis, with size playing only a 
minor role, well behind all other factors.
Although size did not seem to have value for stage clas-
sification, the TD-SPFC considered whether it could be use-
ful in predicting the ability to perform a complete resection. 
However, this was not the case (Supplementary Figure 6B, 
Supplemental Digital Content 7, http://links.lww.com/JTO/
A669); an additional analysis relative to R0 versus R1 versus 
R2 was also not revealing. Therefore, because size only comes 
into play postoperatively among R1,2 patients, there is little 
clinical usefulness for this marker and size was not considered 
further in the stage classification.
Thymoma and Thymic Carcinoma
When analyzed separately, the outcomes followed 
a similar pattern for thymoma and TC as compared with 
all diagnoses (Supplementary Table 2 [Supplemental 
Digital Content 3, http://links.lww.com/JTO/A665] and 
Supplementary Figures 7 [Supplemental Digital Content 
8, http://links.lww.com/JTO/A670] and 8 [Supplemental 
Digital Content 9, http://links.lww.com/JTO/A671]). 
Specifically, there was no clear difference between T1a and 
T1b. T2 (pericardium) showed a higher recurrence rate than 
T1 and a lower recurrence rate than T3; for OS T2 and T3 
were fairly similar. There were too few patients with T4 
tumors to allow a meaningful assessment of outcomes of 
TaBLE 3.  Differences between T Categories
Variable
CIR, R0
(363/4256)a
OS, R0
(506/5932)a
OS, any R
(624/6561)a
HR p HR p HR p
HR vs. adjacent T category
T2 vs. T1 3.10 <0.0001 2.05 0.0002 2.30 <0.0001
T3 vs. T2 1.67 0.025 1.03 NS 1.00 NS
T4 vs. T3 1.30 NS 1.00 NS 0.94 NS
Hazard ratios and statistical differences (χ2) by cox proportional hazards regression 
models, adjusted by diagnosis.
aNumber of events/total number of patients in entire data set for the particular 
analysis.
CIR, cumulative incidence of recurrence; HR, hazard ratio; NS, not significant 
(p values are given if <0.1); OS, overall survival; R0, complete resection.
TaBLE 2.  Total Proportion of Recurrences or Deaths
Recurrences Deaths
T Category % n % n
T1 5 192/3659 7 363/5134
T1a 5 168/3383 7 329/4815
T1b 9 24/276 11 34/319
T2 18 22/124 16 30/187
T3 31 142/455 19 108/588
T3 single 25 59/240 19 65/335
T3 multiple 39 83/215 17 43/253
T4 39 55/1047/18 22 5/23
Total 10 363/4256 9 506/5932
The total number of recurrences or deaths observed at any time out of the total 
number of evaluable R0 resected patients in each category.
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these groups within a specific histological type. There were 
too few NETTs to analyze separately regarding T categories 
(NETT cases were not included in the analyses of TC, but 
only in the analyses of all patients).
DISCUSSION
The TD-SPFC guiding principles were to develop a 
stage classification that was simple and straightforward, glob-
ally applicable, and as much as possible to be consistent with 
the existing classifications.4 This article documents a pro-
posed methodology for the T staging of thymic epithelial neo-
plasms by assigning levels of direct invasion of mediastinal 
structures, based on a retrospective analysis of 8145 cases 
from an international database created by ITMIG and IASLC, 
with validation of groups when available. Hitherto, only the 
Masaoka system had been validated in a large cohort (1320 
patients).18 Key changes from the existing systems are the 
grouping together as “level1” invasion of tumors limited to 
the mediastinum, independent of capsular invasion, and those 
with mediastinal pleural involvement only. “Level 2” is limited 
to pericardium only. Direct involvement of other mediastinal 
structures are grouped as “level 3” (lung, brachial vein, supe-
rior vena cava, chest wall, phrenic nerve) and “level 4” (aorta, 
myocardium, brachiocephalic artery, pulmonary artery). Size 
does not seem to be a prognostic factor.
Previous classification systems have advocated stage I 
disease as being limited to tumors that were either entirely 
encapsulated or lacked a capsule but had no infiltration into 
the mediastinal fat.1 This was to be distinguished from stage II 
disease where the tumor was limited to the mediastinum, with 
division into stages IIA and IIB on the basis of the measured 
extent of extracapsular spread.1,3 Our data show that there is 
no significant difference in overall survival between encap-
sulated tumors and those limited to the mediastinum, with 
only non-significant differences in CIR found in various sub 
analyses. These data are similar to those found in a meta-anal-
ysis undertaken on 2451 cases from 21 publications, which 
also found no difference between stages I and II thymomas.19 
One might question whether the use of adjuvant radiotherapy 
affected the CIR. The TD-SPFC was not able to carry out a 
separate analysis of this, but other systematic reviews have 
suggested that adjuvant radiotherapy does not alter recurrence 
rates in Masaoka stage I or II patients after an R0 resection.20,21
Involvement of the mediastinal pleura has been vari-
ably assigned to stage II or III (or not clearly defined) in prior 
stage classification systems.1 Indeed, the mediastinal pleura is 
poorly defined in anatomical textbooks and is frequently dif-
ficult or impossible to see on microscopic examination. The 
opinion of the thymic domain committee members was split 
on whether there should be subdivision of T1 (level 1) into 
subgroups of T1a and T1b on the basis of extension through 
the mediastinal pleura, with a marginal consensus to distin-
guish these subgroups to facilitate accumulation of further 
evidence to address this in the future.
Most previous classification systems have included 
involvement of many mediastinal structures within a stage 
III group.1 Better distinction of subgroups among these may 
have the greatest utility in defining outcomes and treatment 
strategies. The TD-SPFC was only able to partially evaluate 
this from the available data. We propose a distinction between 
levels 2, 3, and 4 structures, but recognize that prospective 
data and future research may provide yet better ways of distin-
guishing subgroups of these patients.
There are inevitable limitations using a retrospective 
database in relation to amount of detail, varying interpreta-
tions of how a particular data element is defined by different 
institutions, changing definitions and policies over the course 
of the data collection, and questions about the comparability 
of data from different centers despite bearing the same data 
labels. Also, because thymic epithelial tumors are rare, the 
amount of data available for analysis of subgroups is limited. 
Nevertheless, we believe that the data in this analysis are suf-
ficiently robust so that the proposed categories and descrip-
tors for the T component represent a step forward. The timing 
of the AJCC/UICC process limits the availability of sufficient 
prospective data to substantially contribute to the 8th edition 
of the stage classification; however, the ITMIG prospective 
database, which contains much more detail, should provide 
a solid basis for analyzing areas of uncertainty in the future.
In conclusion, this study presents evidence from a 
cohort of more than 8000 patients for the T component of the 
classification of anatomical extent of thymic epithelial neo-
plasms based on four levels of direct invasion of mediastinal 
structures. These can be taken forward for assessment along-
side the N and the M components to produce a robust TNM 
classification system for submission to the 8th edition of TNM 
staging by the AJCC/UICC.
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